The Journal of Nutrition

Ingestive Behavior and Neurosciences

High-dose ω-3 Fatty Acid Plus Vitamin D3

Supplementation Affects Clinical Symptoms
and Metabolic Status of Patients with
Multiple Sclerosis: A Randomized Controlled
Clinical Trial
Ebrahim Kouchaki,1,2 Maryam Afarini,1 Javad Abolhassani,1 Naghmeh Mirhosseini,4 Fereshteh Bahmani,3
Seyed Ali Masoud,1 and Zatollah Asemi3

1
Department of Neurology, School of Medicine; 2 Physiology Research Center; and 3 Research Center for Biochemistry and Nutrition in
Metabolic Diseases, Kashan University of Medical Sciences, Kashan, I.R. Iran; and 4 Pure North S’Energy Foundation, Calgary, Alberta,
Canada

Abstract
Background: Combined omega-3 fatty acid and vitamin D supplementation may improve multiple sclerosis (MS) by
correcting metabolic abnormalities and attenuating oxidative stress and inflammation.
Objective: This study aimed to determine the effects of ω-3 fatty acid and vitamin D cosupplementation on the disability
score and metabolic status of patients with MS.
Methods: This was a randomized, placebo-controlled clinical trial with Expanded Disability Status Scale (EDSS) score
and inflammation as primary outcomes and oxidative stress biomarkers and metabolic profile as secondary outcomes.
Patients, aged 18–55 y, were matched for disease EDSS scores, gender, medications, BMI, and age (n = 53) and
randomly received a combined 2 × 1000 mg/d ω-3 fatty acid and 50,000 IU/biweekly cholecalciferol supplement or
placebo for 12 wk. The placebos were matched in colour, shape, size, packaging, smell, and taste with supplements.
Fasting blood samples were collected at baseline and end of intervention to measure different outcomes. Multiple linear
regression models were used to assess treatment effects on outcomes adjusting for confounding variables.
Results: Patients taking ω-3 fatty acid plus vitamin D supplements showed a significant improvement in EDSS
(β −0.18; 95% CI: −0.33, −0.04; P = 0.01), compared with placebo. Serum high-sensitivity C-reactive protein
(β −1.70 mg/L; 95% CI: −2.49, −0.90 mg/L; P < 0.001), plasma total antioxidant capacity (β +55.4 mmol/L; 95%
CI: 9.2, 101.6 mmol/L; P = 0.02), total glutathione (β +51.14 µmol/L; 95% CI: 14.42, 87.87 µmol/L; P = 0.007), and
malondialdehyde concentrations (β −0.86 µmol/L; 95% CI: −1.10, −0.63 µmol/L; P < 0.001) were significantly improved
in the supplemented group compared with the placebo group. In addition, ω-3 fatty acid and vitamin D cosupplementation
resulted in a significant reduction in serum insulin, insulin resistance, and total/HDL-cholesterol, and a significant increase
in insulin sensitivity and serum HDL-cholesterol concentrations.
Conclusion: Overall, taking ω-3 fatty acid and vitamin D supplements for 12 wk by patients with MS had beneficial
effects on EDSS and metabolic status. This trial was registered at the Iranian website (www.irct.ir) for registration of
clinical trials as IRCT2017090133941N20. J Nutr 2018;148:1–7.

Keywords: ω-3 fatty acid, vitamin D, multiple sclerosis, disability, inflammation, oxidative stress

Introduction and oxidative damage have been suggested as a pathogenic

Multiple sclerosis (MS) is defined as a long-lasting inflammatory mechanism leading to progressive MS (3, 4). In addition, chronic
neurodegenerative disease involving the central nervous system, inflammation in these patients might lead to increased insulin
which affects young and middle-aged adults in the ages ranging resistance and postprandial hyperinsulinemia (5).
from 20 to 55 y (1). MS is evidently more common among To date, the majority of clinical trials in patients with MS
women with ∼60% of MS cases being female (1). Mental have been focused on either dietary supplements like fish oil
illnesses such as depression might be detected in 50–60% or vitamin D (6) or specific diets such as low saturated fat,
of patients with MS (2). Increased inflammatory markers with/without any supplement (7–10), and data on combined

© 2018 American Society for Nutrition. All rights reserved.

Manuscript received March 12, 2018. Initial review completed April 4, 2018. Revision accepted May 8, 2018. 1
First published online 0, 2018; doi: https://doi.org/10.1093/jn/nxy116.
Downloaded from https://academic.oup.com/jn/advance-article-abstract/doi/10.1093/jn/nxy116/5048775
by Universite de Sherbrooke user
on 10 July 2018
 supplementation are scarce. Early studies have reported that Study design
fish oil supplementation significantly decreased inflammatory All patients were matched for disease severity based on EDSS, gender,
cytokines and nitric oxide (NO) catabolites in patients with type of medications, BMI, and age. They were then randomly allocated
MS (10, 11). Previous published trials have documented that into 2 groups to receive either 2 ω-3 fatty acid capsules daily (containing
500 mg DHA and 106 mg EPA) plus vitamin D3 as cholecalciferol
vitamin D supplementation decreased parameters of oxidative
supplements (50,000 IU/biweekly) (n = 26) or sunflower oil capsules
stress and positively influenced other metabolic profiles in these
(placebo, n = 27) for 12 wk. High-DHA fish oil capsules (7.6%
patients (12, 13). However, in another trial of high-dose vitamin EPA + 27% DHA) and sunflower oil placebo capsules were donated by
D3 (cholecalciferol) supplementation (20,000 IU/wk) for 2 y, no Nu-Mega Ingredients Pty Ltd (Melbourne, Australia) and vitamin D3
effects were examined on parameters of systemic inflammation capsules were manufactured by the Pharmaceutical Company (Tabriz,
in patients with MS (14). In addition, fish oil supplementation Iran). The placebos were matched in colour, shape, size, packaging,
at a high dosage of 4 g/d for 12 mo did not improve oxidative smell, and taste with the vitamin D3 and ω-3 fatty acid capsules.
stress in patients with MS (15). The compliance rate was assessed by measuring serum 25(OH)D
We hypothesized that combined omega-3 fatty acid and (25-hydroxyvitamin D) concentrations. Intake of the ω-3 fatty acid,
vitamin D3 supplementation may have synergistic benefits on vitamin D3 , and placebo capsules was monitored through asking
participants to return the medication containers. To increase the
the disability score, mental health, biomarkers of inflammation
compliance rate, all patients received brief daily cellphone reminders to
and oxidative stress, and metabolic status in patients with MS.
take the supplements. Patients were requested to undertake their regular
The current study was therefore conducted to evaluate the physical activity and not to take any extra nutritional supplements
effects of ω-3 fatty acid and vitamin D3 cosupplementation during the 12-wk trial. All patients completed a 3-d food record and 3
on disability score, biomarkers of inflammation and oxidative physical activity records at the baseline of the study, wk 3, 6, and 9, and
stress, and metabolic profile in patients with MS. at the end of the intervention. Daily macro- and micronutrient intakes
were calculated by analyzing food records via nutritionist IV software
(First Databank, San Bruno, CA). In the current study, physical activity
was described as metabolic equivalents (METs) in h/d. To determine the
Methods METs for each patient, we multiplied the duration of reported physical
activity (in h/d) by its related METs coefficient, derived from established
Trial design standard tables (16).
This study was a 12-wk randomized, double-blinded, placebo-
controlled clinical trial.
Sample size
Sample size was calculated using the standard formula for clinical trials,
Patients considering type 1 error (α) of 0.05 and type 2 error (β) of 0.20
Patients in the age range of 18–55 y with relapsing-remitting MS (power = 80%). According to a previous published study (17), we used
(RRMS) according to McDonald criteria, and an expanded disability 2.65 mg/L as the difference in mean (d) and 3.30 mg/L as SD for high-
status scale (EDSS) score of <4.5 (16), who were referred to the Shahid sensitivity C-reactive protein (hs-CRP) as the key variable. Based on
Beheshti Clinic in Kashan, Isfahan State, Iran, between November 2017 this information, 25 individuals were required to be included in each
and January 2018, were included in this study. Eligible patients should treatment group. Considering 5 probable dropouts in each group, the
have all of the following information recorded in their documents final sample size was determined as 30 patients in each group.
collected in the MS clinic: date of birth, gender, age at MS onset,
confirmed RRMS, number of relapses since the onset and delay between Randomization
the first 2 relapses, date of the measurement and EDSS scoring at that Randomization was conducted via computer-generated random num-
time (or <3 mo before or after), familial antecedents of MS (defined bers. Randomization and allocation were concealed from the re-
by the presence of 1 case in first- or second-degree relatives), and searchers and patients until the final analyses were completed. The
the absence of vitamin D3 and ω-3 fatty acid supplementation before randomized allocation sequence, enrolling patients, and allocating them
measurement. Exclusion criteria were as follows: pregnancy or lactating into intervention groups were performed by a trained staff at the MS
during the past 6 mo, a history of nephrolithiasis during the previous clinic.
5 y, menopause, defined as no regular menstruation, and unwillingness
to use appropriate contraception.
Assessment of outcomes
The primary outcomes of this study included EDSS score and
Ethics statements inflammatory markers. Biomarkers of oxidative stress and metabolic
This study followed the Declaration of Helsinki and all patients signed profiles were the secondary outcomes of interest in this study.
the informed consent form. The research was approved by the ethics
committee of Kashan University of Medical Sciences (KAUMS) and Disability score
was registered at the Iranian website for registration of clinical trials EDSS scoring was recorded at baseline and 3 mo later, at the end of the
(http://www.irct.ir) as IRCT2017090133941N20. intervention. Patients who reported new MS symptoms in the phone
interview were invited to the clinic for further evaluation. Relapses,
which were defined as new neurologic deficits, lasting longer than 24
h, with no evidence of an infection (18), were recorded throughout
Supported by a grant no.1396.64 from the Kashan University of Medical
the study. All relapses were confirmed by objective neurological
Sciences. The financial support for conception, design, data analysis, and
manuscript drafting comes from the Research Center for Biochemistry and examination.
Nutrition in Metabolic Diseases, Kashan University of Medical Sciences,
Kashan, Iran. Anthropometric measures
Author disclosures: EK, MA, JA, NM, FB, SAM, and ZA, no conflicts of interest. Patients’ weight and height were measured after an overnight fast, with
Address correspondence to ZA (e-mail: [email protected]). the use of a standard scale (Seca, Hamburg, Germany), at both the onset
Abbreviations used: EDSS, expanded disability status scale; FPG, fasting plasma
of the study and after 12 wk of the trial. BMI was calculated as kg/m2 .
glucose; GSH, total glutathione; hs-CRP, high-sensitivity C-reactive protein; IL-
1β, interleukin-1β; IL-6, interleukin-6; MDA, malondialdehyde; METs, metabolic
equivalents; MS, multiple sclerosis; NF-кB, nuclear factor kappa B; QUICKI, Biomarkers
quantitative insulin sensitivity check index; RRMS, relapsing-remitting MS; TAC, Blood samples were collected, after 12 h fasting, at the beginning and
total antioxidant capacity; TNF-α, tumor necrosis factor-α. end of the trial, at the Kashan reference laboratory. Serum 25(OH)D

2 Kouchaki et al.

Downloaded from https://academic.oup.com/jn/advance-article-abstract/doi/10.1093/jn/nxy116/5048775

by Universite de Sherbrooke user
on 10 July 2018
 concentrations were measured with the use of an ELISA kit (IDS,
Assessed for eligibility (n = 68)
Boldon, United Kingdom) and enzyme-linked immunosorbent assay
with inter- and intra-assay CVs of <7%. Serum hs-CRP concentrations
were measured with the use of an ELISA kit (LDN, Nordhorn,
Germany) with the intra- and interassay CVs <7%. Other biomarkers Excluded (n = 8)
- Not meeting inclusion

Enrollment
were assessed as follows: plasma NO through the use of the Giess criteria (n = 8)
method (19), total antioxidant capacity (TAC) via the ferric reduction
antioxidant power method developed by Benzie and Strain (20),
glutathione (GSH) applying the Beutler et al. method (21), and
malondialdehyde (MDA) concentrations by means of the thiobarbituric
acid reactive substance method (22) with the inter- and intra-assay Randomly assigned (n = 60)
CVs <5%. To measure fasting plasma glucose (FPG) and serum lipid
profiles (total cholesterol, HDL-cholesterol, LDL-cholesterol, VLDL-
cholesterol, and TGs), the study utilized the most commonly used
kits (Pars Azmun, Tehran, Iran). CVs for FPG, total cholesterol,
HDL-cholesterol, LDL-cholesterol, VLDL-cholesterol, and TGs were
1.7%, 1.6%, 1.8%, 1.9%, 2.1%, and 1.8%, respectively. Circulating

Allocation
concentrations of serum insulin were assessed through the use of an Allocated to placebo Allocated to intervention
ELISA kit (Monobind, Lake Forest, CA) with the intra- and interassay (n = 30) (n = 30)
CVs <5%. The HOMA-IR and the quantitative insulin sensitivity check
index (QUICKI) were calculated according to previously established
formulas (23).
Lost to follow-up due to Lost to follow-up due to
moving to another city (n = 2) moving to another city (n = 2)

Follow-up
Statistical methods and not interested to be in and not interested to be in
research (n = 1) research (n = 2)
Anthropometric measures and nutrient intake were compared between
intervention groups, via independent-samples t test. Multiple linear
regression models were used to assess treatment effects on the study
outcomes after adjusting for confounding variables including the
baseline values, age, and BMI. The effect sizes were presented as the
mean differences with 95% CIs. The normality of the model residual
Analysis
Analyzed (n = 27) Analyzed (n = 26)
was tested through the use of the Kolmogorov-Smirnov one-sample
test. Outcome log-transformation was applied if the model residual did
not have a normal distribution (QUICKI, TGs, and VLDL-cholesterol).
Bootstrapping was also used as a sensitivity analysis for CIs and inverse
probability weighting was used to explain loss-to-follow-up, but the FIGURE 1 Summary of patient flow.
results did not change substantially. A P value of <0.05 was considered
as statistically significant. All statistical analyses were conducted via
the Statistical Package for the Social Sciences version 18 (SPSS Inc., and MDA (β −0.86 µmol/L; 95% CI: −1.10, −0.63 µmol/L;
Chicago, IL). P < 0.001) improved significantly in the supplemented group,
compared with the placebo group. In addition, ω-3 fatty acid
and vitamin D3 combination resulted in a significant reduction
in serum insulin (β −2.33 μIU/mL; 95% CI: −4.03, −0.63
Results μIU/mL; P = 0.008), HOMA-IR (β −0.46; 95% CI: −0.83,
At the end of the intervention, 53 patients [treatment (n = 26) −0.08; P = 0.01), and total/HDL-cholesterol (β −0.43; 95%
and placebo (n = 27)] completed the trial (Figure 1). Four CI: −0.85, −0.006; P = 0.04), and a significant increase in
patients in the treatment group and 3 in the placebo group QUICKI (β +0.01; 95% CI: 0.003, 0.02; P = 0.008) and
were excluded from final analyses due to moving to another serum HDL-cholesterol concentrations (β +2.30 mg/dL; 95%
city (n = 4) or loss of interest for participation in the research CI: 0.59, 4.00 mg/dL; P = 0.009) compared with the placebo.
(n = 3). Overall, the compliance rate in this study was high, Other biomarkers of oxidative stress, FPG, and other lipids did
such that >90% of capsules were consumed throughout the
study in both groups. No side effects were reported after
coadministration of ω-3 fatty acid and vitamin D3 capsules in TABLE 1 General characteristics of study patients1
MS patients throughout the study.
Placebo group ω-3 fatty acid plus vitamin
Mean age, height, weight, and BMI at baseline and end-of-
(n = 27) D3 group (n = 26) P2
trial were not significantly different between the intervention
groups (Table 1). Age, y 35.2 ± 9.2 33.3 ± 6.5 0.37
Mean dietary macro- and micronutrient intakes were also Height, cm 161.6 ± 6.4 163.2 ± 8.5 0.41
not significantly different between the 2 groups throughout the Body weight, kg
trial (Table 2). Baseline 65.1 ± 9.9 66.8 ± 11.1 0.53
Our findings showed that the coadministration of ω-3 fatty Wk 12 65.0 ± 10.0 66.8 ± 11.1 0.50
acid and vitamin D3 , for 12 wk, significantly decreased EDSS Change −0.1 ± 0.7 0.1 ± 0.4 0.32
score [β (difference in the mean outcome measures between BMI, kg/m2
treatment groups) −0.18; 95% CI: −0.33, −0.04; P = 0.01] in Baseline 24.9 ± 3.3 25.1 ± 3.9 0.83
patients with MS (Table 3). Moreover, serum hs-CRP (β −1.70 Wk 12 24.8 ± 3.4 25.1 ± 3.9 0.78
mg/L; 95% CI: −2.49, −0.90 mg/L; P < 0.001), plasma TAC Change −0.1 ± 0.3 0.03 ± 0.1 0.26
(β +55.4 mmol/L; 95% CI: 9.2, 101.6 mmol/L; P = 0.02), GSH 1
Data are means ± SDs.
(β +51.14 µmol/L; 95% CI: 14.42, 87.87 µmol/L; P = 0.007), 2
Obtained from independent t test.

Supplementation and multiple sclerosis 3

Downloaded from https://academic.oup.com/jn/advance-article-abstract/doi/10.1093/jn/nxy116/5048775

by Universite de Sherbrooke user
on 10 July 2018
 TABLE 2 Dietary intakes of patients with multiple sclerosis and other possible confounding factors. ω-3 fatty acid might
who were or were not supplemented with ω-3 fatty acid plus be beneficial in MS patients through immune modulation.
vitamin D3 for 12 wk1 Its intake would reduce the synthesis of the proinflammatory
leukotriene B4 and prostaglandin E2 (31) and it can increase
Placebo group ω-3 plus vitamin D3
the synthesis of the less inflammatory leukotriene B5 and
(n = 27) group (n = 26) P2
prostaglandin E3 (32). ω-3 fatty acid intake also would
Energy, kcal/d 2100 ± 196 2186 ± 227 0.14 affect the synthesis of cytokines (33), which in turn might
Carbohydrates, g/d 286 ± 36 297 ± 43 0.34 improve EDSS in these patients. The beneficial impacts of
Protein, g/d 79 ± 20 81 ± 16 0.65 vitamin D3 on mental health in patients with MS can be
Fat, g/d 75 ± 16 79 ± 11 0.35 explained through its role for increasing the expression of the
SFAs, g/d 24 ± 6 26 ± 4 0.37 tyrosine hydroxylase gene and promoting the bioavailability of
PUFAs, g/d 23 ± 6 24 ± 6 0.49 some neurotransmitters such as dopamine, noradrenaline, and
MUFAs, g/d 21 ± 7 22 ± 5 0.55 adrenaline (34, 35).
Cholesterol, mg/d 197 ± 110 219 ± 107 0.46
ω-3 fatty acid, g/d 0.9 ± 0.4 1.0 ± 0.4 0.55
TDF, g/d 18 ± 5 19 ± 4 0.53 Effect on biomarkers of inflammation and oxidative
Vitamin D, µg/d 2.7 ± 0.7 2.9 ± 0.8 0.52 stress
Vegetables, serving/d 3.6 ± 1.1 4.0 ± 1.0 0.26 The cosupplementation of ω-3 fatty acid and vitamin D3
Fruits, serving/d 2.9 ± 0.9 3.0 ± 0.8 0.54 for 12 wk was found to significantly decrease inflammatory
markers including serum hs-CRP and plasma MDA and increase
1
Values are means ± SDs. TDF, total dietary fiber.
plasma total antioxidant capacity and GSH concentrations
2
Obtained from independent t test.
in patients with MS. Our findings were in agreement with
other studies involving ω-3 fatty acid supplementation indi-
not significantly change with ω-3 fatty acid and vitamin D3 cating decreased production of proinflammatory markers such
cosupplementation. as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β),
and IL-6 (36, 37). In a meta-analysis which evaluated the
effects of fish oil supplementation in patients with chronic
heart failure, circulating inflammatory markers decreased after
Discussion 3–12 mo of supplementation (38). We have previously shown
We evaluated the effect of coadministration of ω-3 fatty acid that the combination of ω-3 fatty acid and vitamin D3 for
and vitamin D3 at high doses, to the best of our knowledge for 6 wk had beneficial effects on hs-CRP, TAC, GSH, and MDA
the first time, on disability and metabolic status in patients with in women with gestational diabetes (GDM) (17). Moreover,
MS. The results showed that taking ω-3 fatty acid and vitamin vitamin D3 administration at a dosage of 100,000 IU monthly
D3 supplements together for 12 wk had beneficial effects on for 12 wk decreased oxidative stress mediators of arterial
EDSS score, serum hs-CRP, plasma TAC, GSH, MDA, insulin stiffness in overweight and obese individuals (39). On the
metabolism, HDL-, and total/HDL-cholesterol. other hand, supplementation with 1000 mg EPA and 400 mg
DHA per d for 18 wk did not show any significant effect on
inflammatory markers like hs-CRP and IL-6 concentrations in
Effect on clinical signs
a healthy population (40). In another study, supplementation
Patients with MS are predisposed to multiple complications,
with different doses of EPA plus DHA (300, 600, 900, and
such as increased risk of cardiovascular disease, dyslipidemia
1800 mg/d) for 5 mo did not change IL-6, TNF-α, and
(24), insulin resistance (25), other morbidities, and an increased
CRP concentrations in healthy individuals (41). We also have
mortality rate (26). Combination of ω-3 fatty acid and vitamin
indicated that 50,000 IU/wk vitamin D3 supplements for 8 wk
D3 supplements for 12 wk led to a significant reduction in
did not influence hs-CRP concentrations, yet increased TAC and
these patients’ disabilities. Our findings were in line with other
GSH concentrations in patients with major depressive disorder
studies showing that DHA and EPA supplementation for 2 y
(12). Increased gene expression of peroxisome proliferator-
resulted in a significant reduction in EDSS score in patients
activated receptors by ω-3 fatty acid might inhibit the activation
with MS (27). Furthermore, it was suggested that fish oil given
of nuclear factor kappa B (NF-кB) (42), which reduces the
together with vitamins and dietary advice could improve clinical
production of inflammatory markers. Less production of
outcome in patients newly diagnosed with MS (27). A high-
parathyroid hormone by vitamin D supplementation (43) might
dose vitamin D3 supplement added to routine care of pregnant
be involved in decreasing the production of inflammatory
women with MS was shown to have a significant impact on
factors including CRP. ω-3 fatty acid and vitamin D3 both
EDSS and number of relapses during pregnancy and within 6 mo
were also found to have remarkable anti-inflammatory and
after delivery (28). In another study, vitamin D deficiency was
antioxidant properties (44, 45). Vitamin D3 might decrease
significantly associated with higher risk of disability in patients
production of reactive oxygen species and proinflammatory
with MS (29). However, there are discrepancies among different
cytokines (46).
studies looking into the association of different nutrients with
MS. For example, Ramirez et al. (10) showed that high-dose
fish oil supplementation (4 g/d) for 12 mo did not affect EDSS Effect on glycemic control and lipid profiles
score in patients with RRMS. In a meta-analysis conducted The current study demonstrated that ω-3 fatty acid and
by James et al. (30), there was no significant relation between vitamin D3 cosupplementation for 12 wk was associated
high-dose vitamin D supplementation and risk of MS relapses. with significant improvements in glycemic control, insulin
The inconclusive results of different studies might be related sensitivity, and lipid profiles. We have previously shown that the
to their methodology including doses, administering combined coadministration of vitamin D3 and ω-3 fatty acid to women
compared with individual nutrients, duration of intervention, with GDM for 6 wk had beneficial effects on fasting glucose,
4 Kouchaki et al.

Downloaded from https://academic.oup.com/jn/advance-article-abstract/doi/10.1093/jn/nxy116/5048775

by Universite de Sherbrooke user
on 10 July 2018
 TABLE 3 Expanded disability status scale, biomarkers of inflammation and oxidative stress, and metabolic profiles at baseline and
after the 12-wk intervention in patients with multiple sclerosis that received ω-3 fatty acid plus vitamin D3 or placebo1

ω-3 fatty acid plus vitamin D3 Difference in outcome measures between ω-3 fatty
Placebo group (n = 27) group (n = 26) acid plus vitamin D3 and placebo treatment groups2
Variables Baseline Wk 12 Baseline Wk 12 β (95% CI) P3
Serum 25-hydroxyvitamin D, ng/mL 12.7 ± 2.8 13.0 ± 3.0 14.0 ± 3.1 25.2 ± 7.7 12.53 (10.49, 14.56) <0.001
EDSS 2.4 ± 0.9 2.5 ± 0.9 2.3 ± 0.6 2.2 ± 0.5 −0.18 (−0.33, −0.04) 0.01
Serum hs-CRP, mg/L 3.9 ± 2.4 4.2 ± 2.5 3.7 ± 2.0 2.6 ± 2.3 −1.70 (−2.49, −0.90) <0.001
Plasma NO, μmol/L 36.0 ± 4.0 35.2 ± 4.8 34.2 ± 3.7 34.2 ± 3.9 0.41 (−1.38, 2.21) 0.64
Plasma TAC, mol/L 1.0 ± 0.1 1.0 ± 0.1 1.1 ± 0.1 1.1 ± 0.1 55.4 (9.2, 101.6) 0.02
Plasma GSH, µmol/L 702 ± 119 698 ± 91 751 ± 89 782 ± 108 51.14 (14.42, 87.87) 0.007
Plasma MDA, µmol/L 2.8 ± 0.5 2.9 ± 0.6 3.0 ± 0.6 2.3 ± 0.5 −0.86 (−1.10, −0.63) <0.001
FPG, mg/dL 89.0 ± 8.6 90.4 ± 8.9 90.6 ± 10.3 88.9 ± 9.8 −2.28 (−5.34, 0.78) 0.14
Serum insulin, μIU/mL 12.7 ± 3.9 13.2 ± 3.8 13.4 ± 3.4 11.4 ± 3.9 −2.33 (−4.03, −0.63) 0.008
HOMA-IR 2.8 ± 0.9 2.9 ± 0.9 3.0 ± 1.0 2.5 ± 1.0 −0.46 (−0.83, −0.08) 0.01
QUICKI 0.33 ± 0.01 0.32 ± 0.01 0.32 ± 0.01 0.33 ± 0.02 0.01 (0.003, 0.02) 0.008
Serum TGs, mg/dL 133 ± 61 136 ± 58 126 ± 69 128 ± 62 −1.70 (−13.65, 10.25) 0.78
Serum VLDL-cholesterol, mg/dL 26.7 ± 12.2 27.3 ± 11.5 25.2 ± 13.7 25.6 ± 12.4 −0.34 (−2.73, 2.05) 0.78
Serum total cholesterol, mg/dL 155 ± 32 162 ± 31 159 ± 41 165 ± 40 −1.77 (−10.93, 7.39) 0.94
Serum LDL-cholesterol, mg/dL 85.0 ± 38.2 90.7 ± 37.0 89.5 ± 33.9 92.5 ± 32.3 −3.96 (−11.48, 3.55) 0.29
Serum HDL-cholesterol, mg/dL 43.3 ± 6.8 44.1 ± 6.8 44.0 ± 6.9 46.6 ± 6.6 2.30 (0.59, 4.00) 0.009
Total/HDL-cholesterol 3.7 ± 0.9 3.8 ± 0.9 3.7 ± 1.0 3.6 ± 0.9 −0.43 (−0.85, −0.006) 0.04
1
Data are means ± SDs. EDSS, expanded disability status scale; FPG, fasting plasma glucose; GSH, total glutathione; hs-CRP, high-sensitivity C-reactive protein; MDA,
malondialdehyde; NO, nitric oxide; QUICKI, quantitative insulin sensitivity check index; TAC, total antioxidant capacity.
2
“Outcome measures” refers to the change in values of measures of interest between baseline and wk 12. β, difference in the mean outcome measures between treatment
groups; ω-3 fatty acid plus vitamin D3 group = 1 and placebo group = 0.
3
Obtained from multiple regression model (adjusted for baseline values of each biochemical variable, age, and baseline BMI).

insulin concentrations, HOMA-IR, QUICKI, TGs, and VLDL- Acknowledgments

cholesterol concentrations (47). Supplementation with 2.4 g/d The present study was supported by a grant from the Vice-
EPA + DHA for 8 wk to hemodialysis patients also decreased chancellor for Research, KAUMS, and Iran. The research was
insulin concentrations and HOMA-IR (48). Von Hurst et al. supported by the donation of high-DHA tuna fish oil capsules
(49) determined that vitamin D supplementation at a dosage and sunflower oil placebo capsules from Nu-Mega Ingredients
of 4000 IU/d for 6 mo significantly improved insulin sensitivity Pty Ltd (Melbourne, Australia). We thank Moein Mobini
in healthy women. However, there was controversy regarding for a scientific review and edit of the paper. The authors’
the impact of vitamin D and/or ω-3 fatty acid on glycemic responsibilities were as follows—ZA: conception and design,
control. For example, no significant difference was seen in conducted statistical analysis, and wrote the manuscript, EK,
fasting glucose, insulin, HOMA-IR, LDL-cholesterol, leptin, MA, JA, NM, FB, and SAM: conception, collected the data,
or adiponectin concentrations after the supplementation of and wrote the manuscript; and all authors: approved the final
1800 mg/d ω-3 fatty acid for 4 mo in hemodialysis patients (50). paper.
In another study, vitamin D supplementation with 1000 IU/d for
12 wk did not influence insulin resistance in healthy overweight
or obese women (51). Differences in the design of the studies, References
lack of considering baseline values of dependent biochemical
parameters along with characteristics of study patients, different 1. Hogancamp WE, Rodriguez M, Weinshenker BG. The epidemiology of
multiple sclerosis. Mayo Clin Proc 1997;72:871–8.
dosages and types of ω-3 fatty acid and vitamin D used as
2. Patten SB, Metz LM. Depression in multiple sclerosis. Psychother
well as the duration of the intervention might provide some Psychosom 1997;66:286–92.
reasons for discrepant findings. ω-3 fatty acid might inhibit 3. Fischer MT, Sharma R, Lim JL, Haider L, Frischer JM, Drexhage J,
proinflammatory markers and suppress gene expression of NF- Mahad D, Bradl M, van Horssen J, Lassmann H. NADPH oxidase
кB, and so it could improve markers of insulin metabolism (52). expression in active multiple sclerosis lesions in relation to oxidative
Vitamin D3 might as well improve glycemic control through tissue damage and mitochondrial injury. Brain 2012;135:886–99.
upregulating the insulin receptor genes (53) and increasing the 4. Kallaur AP, Reiche EM, Oliveira SR, Simao AN, Pereira WL, Alfieri
transcription of insulin receptor genes (53). DF, Flauzino T, Proenca CM, Lozovoy MA, Kaimen-Maciel DR et al.
Genetic, immune-inflammatory, and oxidative stress biomarkers as
This study had a few limitations. In the present study, predictors for disability and disease progression in multiple sclerosis.
we did not evaluate circulating fatty acid profiles before and Mol Neurobiol 2017;54:31–44.
after supplementation. Further, this study did not assess gene 5. Penesova A, Vlcek M, Imrich R, Vernerova L, Marko A, Meskova
expression related to inflammatory cytokines and biomarkers M, Grunnerova L, Turcani P, Jezova D, Kollar B. Hyperinsulinemia
of oxidative stress. in newly diagnosed patients with multiple sclerosis. Metab Brain Dis
2015;30:895–901.
In summary, the current study demonstrated that taking ω-3
6. Farinotti M, Vacchi L, Simi S, Di Pietrantonj C, Brait L, Filippini G.
fatty acid and vitamin D3 supplements together for 12 wk by Dietary interventions for multiple sclerosis. Cochrane Database Syst
patients with MS has beneficial effects on their MS disability Rev 2012;12:Cd004192.
score, inflammation and antioxidant capacity, and metabolic 7. Swank RL, Goodwin J. Review of MS patient survival on a Swank low
status including insulin metabolism. saturated fat diet. Nutrition 2003;19:161–2.

Supplementation and multiple sclerosis 5

Downloaded from https://academic.oup.com/jn/advance-article-abstract/doi/10.1093/jn/nxy116/5048775

by Universite de Sherbrooke user
on 10 July 2018
 8. Weinstock-Guttman B, Baier M, Park Y, Feichter J, Lee-Kwen P, 26. Burkill S, Montgomery S, Hajiebrahimi M, Hillert J, Olsson T,
Gallagher E, Venkatraman J, Meksawan K, Deinehert S, Pendergast Bahmanyar S. Mortality trends for multiple sclerosis patients in Sweden
D et al. Low fat dietary intervention with omega-3 fatty acid from 1968 to 2012. Neurology 2017;89:555–62.
supplementation in multiple sclerosis patients. Prostaglandins Leukot 27. Nordvik I, Myhr KM, Nyland H, Bjerve KS. Effect of dietary advice
Essent Fatty Acids 2005;73:397–404. and n-3 supplementation in newly diagnosed MS patients. Acta Neurol
9. Shirvani-Farsani Z, Kakhki MP, Gargari BN, Doosti R, Moghadasi AN, Scand 2000;102:143–9.
Azimi AR, Behmanesh M. The expression of VDR mRNA but not NF- 28. Etemadifar M, Janghorbani M. Efficacy of high-dose vitamin D3
kappaB surprisingly decreased after vitamin D treatment in multiple supplementation in vitamin D deficient pregnant women with multiple
sclerosis patients. Neurosci Lett 2017;653:258–63. sclerosis: preliminary findings of a randomized-controlled trial. Iran J
10. Ramirez-Ramirez V, Macias-Islas MA, Ortiz GG, Pacheco-Moises F, Neurol 2015;14:67–73.
Torres-Sanchez ED, Sorto-Gomez TE, Cruz-Ramos JA, Orozco-Avina 29. Thouvenot E, Orsini M, Daures JP, Camu W. Vitamin D is associated
G, Celis de la Rosa AJ. Efficacy of fish oil on serum of TNFα, IL- with degree of disability in patients with fully ambulatory relapsing-
1β, and IL-6 oxidative stress markers in multiple sclerosis treated with remitting multiple sclerosis. Eur J Neurol 2015;22:564–9.
interferon beta-1b. Oxid Med Cell Longev 2013;2013:709493.
30. James E, Dobson R, Kuhle J, Baker D, Giovannoni G, Ramagopalan
11. Shinto L, Marracci G, Baldauf-Wagner S, Strehlow A, Yadav V, SV. The effect of vitamin D-related interventions on multiple sclerosis
Stuber L, Bourdette D. Omega-3 fatty acid supplementation decreases relapses: a meta-analysis. Mult Scler 2013;19:1571–9.
matrix metalloproteinase-9 production in relapsing-remitting multiple
31. Needleman P, Raz A, Minkes MS, Ferrendelli JA, Sprecher H. Triene
sclerosis. Prostaglandins Leukot Essent Fatty Acids 2009;80:131–6.
prostaglandins: prostacyclin and thromboxane biosynthesis and unique
12. Sepehrmanesh Z, Kolahdooz F, Abedi F, Mazroii N, Assarian A, biological properties. Proc Natl Acad Sci U S A 1979;76:944–8.
Asemi Z, Esmaillzadeh A. Vitamin D supplementation affects the Beck
32. Lee TH, Sethi T, Crea AE, Peters W, Arm JP, Horton CE, Walport
Depression Inventory, insulin resistance, and biomarkers of oxidative
MJ, Spur BW. Characterization of leukotriene B3: comparison of
stress in patients with major depressive disorder: a randomized,
its biological activities with leukotriene B4 and leukotriene B5 in
controlled clinical trial. J Nutr 2016;146:243–8.
complement receptor enhancement, lysozyme release and chemotaxis
13. Bhargava P, Fitzgerald KC, Calabresi PA, Mowry EM. Metabolic of human neutrophils. Clin Sci (Lond) 1988;74:467–75.
alterations in multiple sclerosis and the impact of vitamin D
33. Endres S, Ghorbani R, Kelley VE, Georgilis K, Lonnemann G, van
supplementation. JCI Insight 2017;2:95302.
der Meer JW, Cannon JG, Rogers TS, Klempner MS, Weber PC et al.
14. Rosjo E, Steffensen LH, Jorgensen L, Lindstrom JC, Saltyte Benth J, The effect of dietary supplementation with n-3 polyunsaturated fatty
Michelsen AE, Aukrust P, Ueland T, Kampman MT, Torkildsen O et al. acids on the synthesis of interleukin-1 and tumor necrosis factor by
Vitamin D supplementation and systemic inflammation in relapsing- mononuclear cells. N Engl J Med 1989;320:265–71.
remitting multiple sclerosis. J Neurol 2015;262:2713–21.
34. Khoraminya N, Tehrani-Doost M, Jazayeri S, Hosseini A, Djazayery
15. Sorto-Gomez TE, Ortiz GG, Pacheco-Moises FP, Torres-Sanchez ED, A. Therapeutic effects of vitamin D as adjunctive therapy to fluoxetine
Ramirez-Ramirez V, Macias-Islas MA, de la Rosa AC, Velazquez- in patients with major depressive disorder. Aust N Z J Psychiatry
Brizuela IE. Effect of fish oil on glutathione redox system in multiple 2013;47:271–5.
sclerosis. Am J Neurodegener Dis 2016;5:145–51.
35. Humble MB. Vitamin D, light and mental health. J Photochem Photobiol
16. Ainsworth BE, Haskell WL, Whitt MC, Irwin ML, Swartz AM, Strath B 2010;101:142–9.
SJ, O’Brien WL, Bassett DR, Jr., Schmitz KH, Emplaincourt PO, et al.
36. von Schacky C. n-3 PUFA in CVD: influence of cytokine polymorphism.
Compendium of physical activities: an update of activity codes and
Proc Nutr Soc 2007;66:166–70.
MET intensities. Med Sci Sports Exerc 2000;32:S498–504.
37. Zhao YT, Shao L, Teng LL, Hu B, Luo Y, Yu X, Zhang DF,
17. Razavi M, Jamilian M, Samimi M, Afshar Ebrahimi F, Taghizadeh
Zhang H. Effects of n-3 polyunsaturated fatty acid therapy on plasma
M, Bekhradi R, Seyed Hosseini E, Haddad Kashani H, Karamali
inflammatory markers and N-terminal pro-brain natriuretic peptide in
M, Asemi Z. The effects of vitamin D and omega-3 fatty acids co-
elderly patients with chronic heart failure. J Int Med Res 2009;37:1831–
supplementation on biomarkers of inflammation, oxidative stress and
41.
pregnancy outcomes in patients with gestational diabetes. Nutr Metab
(Lond) 2017;14:80. 38. Xin W, Wei W, Li X. Effects of fish oil supplementation on inflammatory
markers in chronic heart failure: a meta-analysis of randomized
18. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M,
controlled trials. BMC Cardiovasc Disord 2012;12:77.
Fujihara K, Havrdova E, Hutchinson M, Kappos L, et al. Diagnostic
criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. 39. Martins D, Meng YX, Tareen N, Artaza J, Lee JE, Farodolu C, Gibbons
Ann Neurol 2011;69:292–302. G, Norris K. The effect of short term vitamin D supplementation on
the inflammatory and oxidative mediators of arterial stiffness. Health
19. Tatsch E, Bochi GV, da Silva Pereira R, Kober H, Agertt VA, de Campos
(Irvine Calif) 2014;6:1503–11.
MM, Gomes P, Duarte MM, Moresco RN. A simple and inexpensive
automated technique for measurement of serum nitrite/nitrate. Clin 40. Muldoon MF, Laderian B, Kuan DC, Sereika SM, Marsland AL,
Biochem 2011;44:348–50. Manuck SB. Fish oil supplementation does not lower C-reactive protein
or interleukin-6 levels in healthy adults. J Intern Med 2016;279:98–109.
20. Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as
a measure of “antioxidant power”: the FRAP assay. Anal Biochem 41. Flock MR, Skulas-Ray AC, Harris WS, Gaugler TL, Fleming JA,
1996;239:70–6. Kris-Etherton PM. Effects of supplemental long-chain omega-3 fatty
acids and erythrocyte membrane fatty acid content on circulating
21. Beutler E, Gelbart T. Plasma glutathione in health and in patients with
inflammatory markers in a randomized controlled trial of healthy
malignant disease. J Lab Clin Med 1985;105:581–4.
adults. Prostaglandins Leukot Essent Fatty Acids 2014;91:161–8.
22. Janero DR. Malondialdehyde and thiobarbituric acid-reactivity as
42. Rossi A, Kapahi P, Natoli G, Takahashi T, Chen Y, Karin M,
diagnostic indices of lipid peroxidation and peroxidative tissue injury.
Santoro MG. Anti-inflammatory cyclopentenone prostaglandins are
Free Radic Biol Med 1990;9:515–40.
direct inhibitors of IkappaB kinase. Nature 2000;403:103–8.
23. Pisprasert V, Ingram KH, Lopez-Davila MF, Munoz AJ, Garvey WT.
43. Struglia M, Stamerra CA, Di Giosia P, Giorgini P, Capanna C, Grassi D,
Limitations in the use of indices using glucose and insulin levels to
Properzi G, Ferri C. Vitamin D deficiency and endothelial dysfunction
predict insulin sensitivity: impact of race and gender and superiority
in rheumatoid arthritis patients. J Hypertens 2015;33(Suppl 1):e84.
of the indices derived from oral glucose tolerance test in African
Americans. Diabetes Care 2013;36:845–53. 44. Hassan Eftekhari M, Aliasghari F, Babaei-Beigi MA, Hasanzadeh
J. Effect of conjugated linoleic acid and omega-3 fatty acid
24. Keytsman C, Eijnde BO, Hansen D, Verboven K, Wens I. Elevated
supplementation on inflammatory and oxidative stress markers in
cardiovascular risk factors in multiple sclerosis. Mult scler relat disord
atherosclerotic patients. ARYA Atheroscler 2013;9:311–18.
2017;17:220–3.
45. Cetinkalp S, Delen Y, Karadeniz M, Yuce G, Yilmaz C. The effect
25. Oliveira SR, Kallaur AP, Lopes J, Colado Simao AN, Reiche EM, de
of 1alpha,25(OH)2D3 vitamin over oxidative stress and biochemical
Almeida ERD, Morimoto HK, de Carvalho Jennings de Pereira WL,
parameters in rats where type 1 diabetes is formed by streptozotocin. J
Alfieri DF, Flauzino T, et al. Insulin resistance, atherogenicity, and
Diabetes Complications 2009;23:401–8.
iron metabolism in multiple sclerosis with and without depression:
Associations with inflammatory and oxidative stress biomarkers and 46. Jain SK, Micinski D. Vitamin D upregulates glutamate cysteine ligase
uric acid. Psychiatry Res 2017;250:113–20. and glutathione reductase, and GSH formation, and decreases ROS and

6 Kouchaki et al.

Downloaded from https://academic.oup.com/jn/advance-article-abstract/doi/10.1093/jn/nxy116/5048775

by Universite de Sherbrooke user
on 10 July 2018
 MCP-1 and IL-8 secretion in high-glucose exposed U937 monocytes. 50. Gharekhani A, Dashti-Khavidaki S, Lessan-Pezeshki M, Khatami MR.
Biochem Biophys Res Commun 2013;437:7–11. Potential effects of omega-3 fatty acids on insulin resistance and lipid
47. Jamilian M, Samimi M, Ebrahimi FA, Hashemi T, Taghizadeh M, Razavi profile in maintenance hemodialysis patients: a randomized placebo-
M, Sanami M, Asemi Z. The effects of vitamin D and omega-3 fatty controlled trial. Iran J Kidney Dis 2016;10:310–18.
acid co-supplementation on glycemic control and lipid concentrations 51. Salehpour A, Shidfar F, Hosseinpanah F, Vafa M, Razaghi M, Amiri
in patients with gestational diabetes. J Clin Lipidol 2017;11:459– F. Does vitamin D3 supplementation improve glucose homeostasis in
68. overweight or obese women? A double-blind, randomized, placebo-
48. Rasic-Milutinovic Z, Perunicic G, Pljesa S, Gluvic Z, Sobajic S, controlled clinical trial. Diabet Med 2013;30:1477–81.
Djuric I, Ristic D. Effects of N-3 PUFAs supplementation on insulin 52. Bellenger J, Bellenger S, Bataille A, Massey KA, Nicolaou A, Rialland M,
resistance and inflammatory biomarkers in hemodialysis patients. Ren Tessier C, Kang JX, Narce M. High pancreatic n-3 fatty acids prevent
Fail 2007;29:321–9. STZ-induced diabetes in fat-1 mice: inflammatory pathway inhibition.
49. von Hurst PR, Stonehouse W, Coad J. Vitamin D supplementation Diabetes 2011;60:1090–9.
reduces insulin resistance in South Asian women living in New Zealand 53. Maestro B, Molero S, Bajo S, Davila N, Calle C. Transcriptional
who are insulin resistant and vitamin D deficient – a randomised, activation of the human insulin receptor gene by 1,25-dihydroxyvitamin
placebo-controlled trial. Br J Nutr 2010;103:549–55. D(3). Cell Biochem Funct 2002;20:227–32.

Supplementation and multiple sclerosis 7

Downloaded from https://academic.oup.com/jn/advance-article-abstract/doi/10.1093/jn/nxy116/5048775

by Universite de Sherbrooke user
on 10 July 2018